Taysha Gene Therapies
Taysha Gene Therapies develops gene therapies targeting severe monogenic diseases of the central nervous system, utilizing adeno-associated virus (AAV) vectors for precise gene delivery. Their lead candidate, TSHA-102, aims to treat Rett syndrome, a genetic disorder causing severe intellectual disability in females.
- Biotechnology
Funding
Raised to date
$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many severe central nervous system (CNS) disorders stem from mutations in a single gene (monogenic diseases), presenting significant challenges for effective treatment. Traditional therapeutic approaches often fail to address the underlying genetic cause of these conditions, leading to limited symptomatic relief and poor long-term outcomes.
Solution
Taysha Gene Therapies is developing gene therapies that target severe monogenic diseases of the CNS. The company utilizes adeno-associated virus (AAV) vectors to deliver functional genes directly to affected cells, aiming to correct the underlying genetic defect. Their lead candidate, TSHA-102, is designed to treat Rett syndrome, a genetic disorder that causes severe intellectual disability, particularly in females. Taysha's approach focuses on maximizing the potential for successful treatment delivery to patients with devastating diseases.
Target Audience
The primary target audience includes patients suffering from severe monogenic diseases of the central nervous system, as well as their families and caregivers.
Features
- Utilizes AAV vectors for targeted gene delivery to the CNS.
- TSHA-102, the lead candidate, specifically targets Rett syndrome.
- Focus on monogenic diseases, addressing the root cause of CNS disorders.